DOCSLIB.ORG

Recurrent PPP2R1A Mutations in Uterine Cancer Act Through A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recurrent PPP2R1A Mutations in Uterine Cancer Act Through A Published OnlineFirst August 2, 2016; DOI: 10.1158/0008-5472.CAN-15-3342 Cancer Molecular and Cellular Pathobiology Research Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth Dorien Haesen1, Layka Abbasi Asbagh2, Rita Derua1, Antoine Hubert1, Stefanie Schrauwen3, Yana Hoorne1,Fred eric Amant3, Etienne Waelkens1, Anna Sablina2, and Veerle Janssens1 Abstract Somatic missense mutations in the Ser/Thr protein phospha- inhibitor TIPRL1. Dominant-negative Aa mutants retain bind- tase 2A (PP2A) Aa scaffold subunit gene PPP2R1A are among ing to specific subunits of the B56/B0 family and form substrate the few genomic alterations that occur frequently in serous trapping complexes with impaired phosphatase activity via endometrial carcinoma (EC) and carcinosarcoma, two clinically increased recruitment of TIPRL1. Accordingly, overexpression aggressive subtypes of uterine cancer with few therapeutic of the Aa mutants in EC cells harboring wild-type PPP2R1A options. Previous studies reported that cancer-associated Aa increased anchorage-independent growth and tumor formation, mutants exhibit defects in binding to other PP2A subunits and and triggered hyperphosphorylation of oncogenic PP2A-B56/B0 contribute to cancer development by a mechanism of haploin- substrates in the GSK3b, Akt, and mTOR/p70S6K signaling sufficiency. Here we report on the functional significance of the pathways. TIPRL1 silencing restored GSK3b phosphorylation most recurrent PPP2R1A mutations in human EC, which cluster and rescued the EC cell growth advantage. Our results reveal in Aa HEAT repeats 5 and 7. Beyond predicted loss-of-function how PPP2R1A mutations affect PP2A function and oncogenic effects on the formation of a subset of PP2A holoenzymes, we signaling, illuminating the genetic basis for serous EC develop- discovered that Aa mutants behave in a dominant-negative ment and its potential control by rationally targeted therapies. manner due to gain-of-function interactions with the PP2A Cancer Res; 76(19); 5719–31. Ó2016 AACR. Introduction refs. 2–9). PPP2R1A aberrations occur early during progression in the precursor lesions (3), are distinctive for the serous Althoughnotascommonasendometrioid carcinoma (type subtype (6), and clearly distinguish uterine serous carcinomas I), serous uterine carcinoma (type II) is a highly aggressive from the clinicopathological similar ovarian high-grade serous disease characterized by high mortality due to a tendency for carcinomas (1, 7, 8). In the highly aggressive uterine carcino- early metastasis and resistance to chemotherapy (1). While sarcomas and undifferentiated carcinomas, PPP2R1A mutation genome-wide molecular changes in low grade endometrioid is also frequent (Supplementary Table S1). PPP2R1A encodes carcinomas have been revealed through The Cancer Genome the Aa subunit of type 2A protein phosphatases (PP2A), Atlas (2), the molecular changes associated with serous endo- suggesting a prominent, but so far unexplored, role for PP2A metrial cancer (EC) pathogenesis have only recently started to in the etiology of these cancers. emerge. Besides TP53 mutation (in 80%–95% of cases), rela- PP2A phosphatases are well-recognized human tumor sup- tively few additional molecular genetic aberrations can be pressors (10). They consist of a catalytic C subunit (PP2Ac), a found in these cancers, the most prevalent being alterations structural A subunit and one of multiple regulatory B-type in PPP2R1A, PIK3CA, FBXW7, CCNE1, and CHD4 (3–5). subunits defining substrate specificity of the holoenzyme Specifically, PPP2R1A is mutated in 18.4% to 43.2% of (11). Because different isoforms exist of A, B, and C subunits, all cases, depending on the study (Supplementary Table S1; their combination results in numerous PP2A holoenzymes, each with different signaling functions in a wide variety of physiological processes (12). The A subunit forms the flexible 1Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium. 2VIB scaffold between the C and B-type subunits, and is composed of Center for the Biology of Disease, Department of Human Genetics, KU 15 HEAT (Huntington, elongation factor 3, A, TOR) motifs 3 Leuven, Leuven, Belgium. Laboratory of Gynaecological Oncology, (13). Biochemical and structural studies have demonstrated Department of Oncology, KU Leuven, Leuven, Belgium. that interaction with a regulatory B-type subunit is mediated Note: Supplementary data for this article are available at Cancer Research by HEAT repeats (HR) 1–8, while interaction with C occurs Online (http://cancerres.aacrjournals.org/). through HR 11–15 (14–18). Despite these different interaction Corresponding Author: Veerle Janssens, University of Leuven (KU Leuven), domains, C and B subunit binding to the A subunit does Gasthuisberg O&N1, Herestraat 49, PO-box 901, B-3000 Leuven, Belgium. Phone: not occur independently from each other (19). For instance, 32-16-330-684; Fax: 32-16-330-735; E-mail: [email protected] N-terminal deletions of Aa inhibit C binding (14), and B55/Ba doi: 10.1158/0008-5472.CAN-15-3342 and B56/B0g3 do not bind to a C-terminally truncated Aa Ó2016 American Association for Cancer Research. (15, 20), while PR72/B" does (20). This suggests cooperativity www.aacrjournals.org 5719 Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst August 2, 2016; DOI: 10.1158/0008-5472.CAN-15-3342 Haesen et al. between specific B-type subunits and C in binding the A Cell lines subunit, while other B-type subunits may bind A independently HEK293, HEK293T, and HEC-1-A (ATCC), characterized by from C (21). Particularly the conserved C-terminal tail of the C Short Tandem Repeat profiling, were used at low passage number subunit provides additional, stabilizing contacts with B55/B (<15) immediately after receipt or after resuscitation from early and most B56/B0 subunits, but not B56/B0d,PR72/B"orstriatin/ made stocks. B"', to promote holoenzyme assembly (22). Thus, the deter- minants governing PP2A trimer assembly are significantly Lentiviral transduction dependent on the B-type subunit that is incorporated. HEK293T cells were transfected with WT/mutant Aa cloned While some PP2A complexes may be proto-oncogenic into lentiviral pLA CMV N-Flag, or with empty vector alone, in (23–25), most PP2A trimers suppress oncogenic signaling the presence of pCMV-deltaR8.91 and pMD.G-VSVG, using events (12, 26, 27). Hence, inhibition of PP2A—in the pres- Turbofect (Thermo Scientific). Lentiviral TIPRL1 shRNAs or GFP ence of oncogenic RasV12—is an absolute requirement to shRNA control (Supplementary Table S2), originally cloned in achieve full transformation of human epithelial cells immor- pLKO.1-puro (TRC 1/1.5 human shRNA library), were generated talized by expression of telomerase and SV40 large T (26–29). similarly. Twenty-four hours later, the supernatant was used to There is increasing evidence of PP2A deregulation in human transduce HEC-1-A EC cells. solid cancers and hematologic malignancies (30–32). Partic- ularly, cancer-associated missense mutations have been re- PP2A subunit binding assays ported in PPP2R1A and PPP2R1B, encoding the nonredundant HEK293 cells were transfected with appropriate PP2A sub- Aa and Ab subunits. Inactivating Ab mutations occur with unit expression vectors using PEI. 48 hours post-transfection, high frequency (up to 15%) in lung and colon cancers (33), lysates were prepared in NET buffer, and GST pulldowns, FLAG while Aa mutations have less frequently (up to 7%) been pulldowns, HA pulldowns or GFP-trapping were executed as reported in melanoma, lung and breast carcinoma (34). Most described (40). Bound proteins were boiled in 2x NuPage sample Ab and all Aa mutations affect PP2A holoenzyme formation, buffer (Invitrogen), and analyzed by immunoblotting on 4% either by interrupting interaction between A and C subunits, to 12% gels (BioRad). Membranes were blocked in 5% milk in between A and all or specific B-type subunits, or both (26, 28, TBS/0.1% Tween-20, developed with primary antibodies (Sup- 35, 36). For the characterized Aa mutants E64D/G and plementary Table S3), horseradish peroxidase-coupled secondary R418W, these binding defects result in functional haploinsuf- antibodies (DAKO) and chemiluminescence (Westernbright ficiency that promotes transformation via activation of ECL-HRP, Isogen Life Science). Densitometric quantification was the PI3K/Akt pathway (28). Accordingly, heterozygous Aa done with ImageJ. For statistics, we applied one-way multiple E64D/G knock-in mice show increased susceptibility to ben- comparisons ANOVA to the average values of all quantified bands zopyrene-induced lung cancerogenesis (37). of a given condition on a given gel. Here, we characterized 11 PPP2R1A missense mutants, commonly observed in serous uterine carcinoma. All these "IP-on-IP" approach Aa mutations are heterozygous, cluster in HEAT repeats 5 or HEK293 cells were cotransfected with expression vectors 7, and many of them are recurrent (Supplementary Table S1), for EGFP-TEV-B56d (or B56g1) and HA-Aa (WT or mutant). also in other cancer types (38). In concordance with the Forty-eight hours later, GFP-trapping was performed, and observed genetic data, our biochemical and functional assays the trapped complexes were incubated overnight at 4Cwith revealed a dominant mechanism-of-action of these mutants 0.2 mg/mL recombinant Tobacco
Load more

Recommended publications
  • MAP4K4 Expression in Cardiomyocytes: Multiple Isoforms, Multiple Phosphorylations and Interactions with Striatins
    MAP4K4 expression in cardiomyocytes: multiple isoforms, multiple phosphorylations and interactions with striatins Article Published Version Creative Commons: Attribution 4.0 (CC-BY) Open access Fuller, S. J., Edmunds, N. S., McGuffin, L. J. ORCID: https://orcid.org/0000-0003-4501-4767, Hardyman, M. A., Cull, J. J., Alharbi, H. O., Meijles, D. N., Sugden, P. H. and Clerk, A. ORCID: https://orcid.org/0000-0002-5658-0708 (2021) MAP4K4 expression in cardiomyocytes: multiple isoforms, multiple phosphorylations and interactions with striatins. Biochemical Journal, 478 (11). pp. 2121-2143. ISSN 0264- 6021 doi: https://doi.org/10.1042/BCJ20210003 Available at http://centaur.reading.ac.uk/98442/ It is advisable to refer to the publisher’s version if you intend to cite from the work. See Guidance on citing . Published version at: http://dx.doi.org/10.1042/BCJ20210003 To link to this article DOI: http://dx.doi.org/10.1042/BCJ20210003 Publisher: Portland Press All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading’s research outputs online Biochemical Journal (2021) 478 2121–2143 https://doi.org/10.1042/BCJ20210003 Research Article MAP4K4 expression in cardiomyocytes: multiple isoforms, multiple phosphorylations and interactions with striatins Stephen J. Fuller1, Nick S. Edmunds1, Liam J. McGuffin1, Michelle A. Hardyman1, Joshua J. Cull1, Hajed O. Alharbi1, Daniel N. Meijles2, Peter H.
    [Show full text]
  • Supplementary Table S1. Upregulated Genes Differentially
    Supplementary Table S1. Upregulated genes differentially expressed in athletes (p < 0.05 and 1.3-fold change) Gene Symbol p Value Fold Change 221051_s_at NMRK2 0.01 2.38 236518_at CCDC183 0.00 2.05 218804_at ANO1 0.00 2.05 234675_x_at 0.01 2.02 207076_s_at ASS1 0.00 1.85 209135_at ASPH 0.02 1.81 228434_at BTNL9 0.03 1.81 229985_at BTNL9 0.01 1.79 215795_at MYH7B 0.01 1.78 217979_at TSPAN13 0.01 1.77 230992_at BTNL9 0.01 1.75 226884_at LRRN1 0.03 1.74 220039_s_at CDKAL1 0.01 1.73 236520_at 0.02 1.72 219895_at TMEM255A 0.04 1.72 201030_x_at LDHB 0.00 1.69 233824_at 0.00 1.69 232257_s_at 0.05 1.67 236359_at SCN4B 0.04 1.64 242868_at 0.00 1.63 1557286_at 0.01 1.63 202780_at OXCT1 0.01 1.63 1556542_a_at 0.04 1.63 209992_at PFKFB2 0.04 1.63 205247_at NOTCH4 0.01 1.62 1554182_at TRIM73///TRIM74 0.00 1.61 232892_at MIR1-1HG 0.02 1.61 204726_at CDH13 0.01 1.6 1561167_at 0.01 1.6 1565821_at 0.01 1.6 210169_at SEC14L5 0.01 1.6 236963_at 0.02 1.6 1552880_at SEC16B 0.02 1.6 235228_at CCDC85A 0.02 1.6 1568623_a_at SLC35E4 0.00 1.59 204844_at ENPEP 0.00 1.59 1552256_a_at SCARB1 0.02 1.59 1557283_a_at ZNF519 0.02 1.59 1557293_at LINC00969 0.03 1.59 231644_at 0.01 1.58 228115_at GAREM1 0.01 1.58 223687_s_at LY6K 0.02 1.58 231779_at IRAK2 0.03 1.58 243332_at LOC105379610 0.04 1.58 232118_at 0.01 1.57 203423_at RBP1 0.02 1.57 AMY1A///AMY1B///AMY1C///AMY2A///AMY2B// 208498_s_at 0.03 1.57 /AMYP1 237154_at LOC101930114 0.00 1.56 1559691_at 0.01 1.56 243481_at RHOJ 0.03 1.56 238834_at MYLK3 0.01 1.55 213438_at NFASC 0.02 1.55 242290_at TACC1 0.04 1.55 ANKRD20A1///ANKRD20A12P///ANKRD20A2///
    [Show full text]
  • High-Throughput Discovery of Novel Developmental Phenotypes
    High-throughput discovery of novel developmental phenotypes The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Dickinson, M. E., A. M. Flenniken, X. Ji, L. Teboul, M. D. Wong, J. K. White, T. F. Meehan, et al. 2016. “High-throughput discovery of novel developmental phenotypes.” Nature 537 (7621): 508-514. doi:10.1038/nature19356. http://dx.doi.org/10.1038/nature19356. Published Version doi:10.1038/nature19356 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32071918 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nature. Manuscript Author Author manuscript; Manuscript Author available in PMC 2017 March 14. Published in final edited form as: Nature. 2016 September 22; 537(7621): 508–514. doi:10.1038/nature19356. High-throughput discovery of novel developmental phenotypes A full list of authors and affiliations appears at the end of the article. Abstract Approximately one third of all mammalian genes are essential for life. Phenotypes resulting from mouse knockouts of these genes have provided tremendous insight into gene function and congenital disorders. As part of the International Mouse Phenotyping Consortium effort to generate and phenotypically characterize 5000 knockout mouse lines, we have identified 410 Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms #Corresponding author: [email protected].
    [Show full text]
  • The MAP4K4-STRIPAK Complex Promotes Growth and Tissue Invasion In
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.07.442906; this version posted May 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The MAP4K4-STRIPAK complex promotes growth and tissue invasion in 2 medulloblastoma 3 Jessica Migliavacca1, Buket Züllig1, Charles Capdeville1, Michael Grotzer2 and Martin Baumgartner1,* 4 1 Division of Oncology, Children’s Research Center, University Children’s Hospital Zürich, Zürich, 5 Switzerland 6 2 Division of Oncology, University Children’s Hospital Zürich, Zürich, Switzerland 7 8 *e-mail: [email protected] 9 10 Abstract 11 Proliferation and motility are mutually exclusive biological processes associated with cancer that depend 12 on precise control of upstream signaling pathways with overlapping functionalities. We find that STRN3 13 and STRN4 scaffold subunits of the STRIPAK complex interact with MAP4K4 for pathway regulation in 14 medulloblastoma. Disruption of the MAP4K4-STRIPAK complex impairs growth factor-induced 15 migration and tissue invasion and stalls YAP/TAZ target gene expression and oncogenic growth. The 16 migration promoting functions of the MAP4K4-STRIPAK complex involve the activation of novel PKCs 17 and the phosphorylation of the membrane targeting S157 residue of VASP through MAP4K4. The anti- 18 proliferative effect of complex disruption is associated with reduced YAP/TAZ target gene expression 19 and results in repressed tumor growth in the brain tissue. This dichotomous functionality of the STRIPAK 20 complex in migration and proliferation control acts through MAP4K4 regulation in tumor cells and 21 provides relevant mechanistic insights into novel tumorigenic functions of the STRIPAK complex in 22 medulloblastoma.
    [Show full text]
  • Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts
    Author Manuscript Published OnlineFirst on October 18, 2012; DOI: 10.1158/0008-5472.CAN-12-1667 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition Peter Kalev1, Michal Simicek1, Iria Vazquez1, Sebastian Munck1, Liping Chen2, Thomas Soin1, Natasha Danda1, Wen Chen2 and Anna Sablina1,* 1VIB Center for the Biology of Disease; Center for Human Genetics, KULeuven, Leuven 3000 Belgium 2Department of Toxicology, Faculty of Preventive Medicine, Guangdong Provincial Key Laboratory of Food, Nutrition and Health, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China *Corresponding author information: [email protected] Contact information: Anna A. Sablina, Ph.D. CME Department, KULeuven O&N I Herestraat 49, bus 602 Leuven, Belgium 3000 Tel: +3216330790 Fax: +3216330145 Running title: The role of PPP2R2A in DNA repair Keywords: PP2A, ATM, DNA repair, cancer, PARP inhibition Conflict of interests: The authors claim no conflict of interest. - 1 - Downloaded from cancerres.aacrjournals.org on September 27, 2021. © 2012 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 18, 2012; DOI: 10.1158/0008-5472.CAN-12-1667 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Reversible phosphorylation plays a critical role in DNA repair. Here we report the results of a loss-of-function screen that identifies the PP2A heterotrimeric serine/threonine phosphatases PPP2R2A, PPP2R2D, PPP2R5A and PPP2R3C in double-strand break (DSB) repair. In particular, we found that PPP2R2A-containing complexes directly dephosphorylated ATM at S367, S1893, and S1981 to regulate its retention at DSB sites.
    [Show full text]
  • STRIPAK Complexes in Cell Signaling and Cancer
    Oncogene (2016), 1–9 © 2016 Macmillan Publishers Limited All rights reserved 0950-9232/16 www.nature.com/onc REVIEW STRIPAK complexes in cell signaling and cancer Z Shi1,2, S Jiao1 and Z Zhou1,3 Striatin-interacting phosphatase and kinase (STRIPAK) complexes are striatin-centered multicomponent supramolecular structures containing both kinases and phosphatases. STRIPAK complexes are evolutionarily conserved and have critical roles in protein (de) phosphorylation. Recent studies indicate that STRIPAK complexes are emerging mediators and regulators of multiple vital signaling pathways including Hippo, MAPK (mitogen-activated protein kinase), nuclear receptor and cytoskeleton remodeling. Different types of STRIPAK complexes are extensively involved in a variety of fundamental biological processes ranging from cell growth, differentiation, proliferation and apoptosis to metabolism, immune regulation and tumorigenesis. Growing evidence correlates dysregulation of STRIPAK complexes with human diseases including cancer. In this review, we summarize the current understanding of the assembly and functions of STRIPAK complexes, with a special focus on cell signaling and cancer. Oncogene advance online publication, 15 February 2016; doi:10.1038/onc.2016.9 INTRODUCTION in the central nervous system and STRN4 is mostly abundant in Recent proteomic studies identified a group of novel multi- the brain and lung, whereas STRN3 is ubiquitously expressed in 5–9 component complexes named striatin (STRN)-interacting phos- almost all tissues. STRNs share a
    [Show full text]
  • STRIPAK Directs PP2A Activity Toward MAP4K4 to Promote Oncogenic Transformation
    bioRxiv preprint doi: https://doi.org/10.1101/823096; this version posted October 29, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation Jong Wook Kim1,2,7,8*, Christian Berrios2,4*, Miju Kim1,2*, Amy E. Schade2,4*, Guillaume Adelmant5, Huwate Yeerna7, Emily Damato1, Amanda Balboni Iniguez1,6, Selene K. Swanson9, Laurence Florens9, Michael P. Washburn9.10, Kim Stegmaier1,6, Nathaniel S. Gray5, Pablo Tamayo7,8, Ole Gjoerup2, Jarrod A. Marto5, James A. DeCaprio2,3,4,†, William C. Hahn1, 2, 3,† 1Broad Institute of Harvard and MIT, Cambridge MA. 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA. 3Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston MA. 4Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, MA. 5Department of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston MA. 6Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA. 7Division of Medical Genetics, School of Medicine, UC San Diego, CA. 8Moores Cancer Center, University of California, San Diego, CA. 9Stowers Institute for Medical Research, Kansas City, MO 64110 10Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160 * These authors contributed equally to the work. †Co-senior authors 1 bioRxiv preprint doi: https://doi.org/10.1101/823096; this version posted October 29, 2019.
    [Show full text]
  • Striatin-3G Inhibits Estrogen Receptor Activity by Recruiting a Protein Phosphatase
    199 Striatin-3g inhibits estrogen receptor activity by recruiting a protein phosphatase Bailin Tan, Xinghua Long1, Harikrishna Nakshatri2, Kenneth P Nephew1 and Robert M Bigsby Department of Obstetrics and Gynecology University School of Medicine, 975 West Walnut Street (IB360), Indianapolis, Indiana 46202, USA 1Department of Medical Sciences Program, Indiana University School of Medicine, Bloomington, Indianapolis, Indiana 47405, USA 2Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA (Correspondence should be addressed to R M Bigsby; Email: [email protected]) Abstract A splicing variant of rat striatin-3 (rSTRN3g) was found to associate with estrogen receptor-a (ERa) in a ligand-dependent manner. In two-hybrid and pull-down analyses, estradiol induced an interaction between rSTRN3g and ERa. STRN3g protein was found in nuclear extracts from rat uterus and human cell lines. Overexpression of rSTRN3g induced a decrease in ERa transcriptional activity but had no effect on ERb activity. Immunoprecipitation analyses showed that rSTRN3g interacts with both the ERa and the catalytic subunit of protein phosphatase 2A (PP2A(C)). The transrepressor action of rSTRN3g was overcome by okadaic acid, an inhibitor of PP2A(C), and by cotransfection of PP2A(C) siRNA. rSTRN3g caused dephosphorylation of ERa at serine 118 and this was abrogated by okadaic acid. ERa lacking phosphorylation sites at either serine 118 or 167 was insensitive to the corepressor action of rSTRN3g. These observations suggest that an rSTRN3g-PP2A(C) complex is recruited to agonist-activated ERa, thereby leading to its dephosphorylation and inhibiting transcription. Journal of Molecular Endocrinology (2008) 40, 199–210 Introduction occurs early after stimulation and is maintained through at least 24 h.
    [Show full text]
  • International Tables for Crystallography
    International Tables for Crystallography Volume G: Definition and exchange of crystallographic data Edited by S. R. Hall and B. McMahon Chapter 3.6. Classification and use of macromolecular data (P. M. D. Fitzgerald, J. D. Westbrook, P. E. Bourne, B. McMahon, K. D. Watenpaugh and H. M. Berman) Author(s) of this paper may load this reprint on their own web site provided that this cover page is retained. Republication of this article or its storage in electronic databases or the like is not permitted without prior permission in writing from the IUCr. Volume G describes the standard data exchange and archival file format (CIF) used throughout crys- tallography. It provides in-depth information vital for small-molecule, inorganic and macromolecular crystallographers, mineralogists, chemists, materials scientists, solid-state physicists and others who wish to record or use the results of a single-crystal or powder diffraction experiment. The volume also provides the detailed data ontology necessary for programmers and database managers to design interoperable computer applications. The accompanying CD-ROM contains the CIF dictionaries in machine-readable form and a collection of libraries and utility programs. Volume This volume is an essential guide and reference for programmers of crystallographic software, data managers handling crystal-structure information and practising crystallographers who need to use CIF. GDefinition and exchange of crystallographic data Edited by S. R. Hall and B. McMahon for CRYSTALLOGRAPHY First edition INTERNATIONAL TABLES For more information and an order form, please visit it.iucr.org/g International Tables Online is available from it.iucr.org c International Union of Crystallography International Tables for Crystallography (2006).
    [Show full text]
  • New Clinical Insights and Physical Mapping of FOXG1-Regulatory Elements
    European Journal of Human Genetics (2012) 20, 1216–1223 & 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12 www.nature.com/ejhg ARTICLE 14q12 and severe Rett-like phenotypes: new clinical insights and physical mapping of FOXG1-regulatory elements Lila Allou1,15, Laetitia Lambert1,2,3,15, Daniel Amsallem4, Eric Bieth5, Patrick Edery6,7, Anne Destre´e8, Franc¸ois Rivier9,DavidAmor10, Elizabeth Thompson11, Julian Nicholl12, Michael Harbord13,ChristopheNemos1, Aline Saunier14, Aissa Moustaı¨ne14, Adeline Vigouroux5, Philippe Jonveaux1,14 and Christophe Philippe*,1,14 The Forkhead box G1 (FOXG1) gene has been implicated in severe Rett-like phenotypes. It encodes the Forkhead box protein G1, a winged-helix transcriptional repressor critical for forebrain development. Recently, the core FOXG1 syndrome was defined as postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and dysgenesis of the corpus callosum. We present seven additional patients with a severe Rett-like neurodevelopment disorder associated with de novo FOXG1 point mutations (two cases) or 14q12 deletions (five cases). We expand the mutational spectrum in patients with FOXG1-related encephalopathies and precise the core FOXG1 syndrome phenotype. Dysgenesis of the corpus callosum and dyskinesia are not always present in FOXG1-mutated patients. We believe that the FOXG1 gene should be considered in severely mentally retarded patients (no speech-language) with severe acquired microcephaly ( À4toÀ6 SD) and few clinical features suggestive of Rett syndrome. Interestingly enough, three 14q12 deletions that do not include the FOXG1 gene are associated with phenotypes very reminiscent to that of FOXG1-mutation-positive patients. We physically mapped a putative long-range FOXG1-regulatory element in a 0.43 Mb DNA segment encompassing the PRKD1 locus.
    [Show full text]
  • Recovering Protein-Protein and Domain-Domain Interactions from Aggregation of IP-MS Proteomics of Coregulator Complexes
    Recovering Protein-Protein and Domain-Domain Interactions from Aggregation of IP-MS Proteomics of Coregulator Complexes Amin R. Mazloom1, Ruth Dannenfelser1, Neil R. Clark1, Arsen V. Grigoryan2, Kathryn M. Linder2, Timothy J. Cardozo2, Julia C. Bond1, Aislyn D. W. Boran1, Ravi Iyengar1, Anna Malovannaya3, Rainer B. Lanz3, Avi Ma’ayan1* 1 Department of Pharmacology and Systems Therapeutics, Systems Biology Center New York (SBCNY), Mount Sinai School of Medicine, New York, New York, United States of America, 2 Department of Pharmacology, New York University School of Medicine, New York, New York, United States of America, 3 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America Abstract Coregulator proteins (CoRegs) are part of multi-protein complexes that transiently assemble with transcription factors and chromatin modifiers to regulate gene expression. In this study we analyzed data from 3,290 immuno-precipitations (IP) followed by mass spectrometry (MS) applied to human cell lines aimed at identifying CoRegs complexes. Using the semi- quantitative spectral counts, we scored binary protein-protein and domain-domain associations with several equations. Unlike previous applications, our methods scored prey-prey protein-protein interactions regardless of the baits used. We also predicted domain-domain interactions underlying predicted protein-protein interactions. The quality of predicted protein-protein and domain-domain interactions was evaluated using known binary interactions from the literature, whereas one protein-protein interaction, between STRN and CTTNBP2NL, was validated experimentally; and one domain- domain interaction, between the HEAT domain of PPP2R1A and the Pkinase domain of STK25, was validated using molecular docking simulations.
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]